March 17−21, 2023, New Orleans, LA

American Academy of Dermatology (AAD)

March 25−29, 2022, Boston, MA

American Academy of Dermatology (AAD)

American Academy of Dermatology (AAD)

poster icon

Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results

C. Hsu, R. Snyder, L. Clore, V. Jain, A. Giménez-Arnau, K. Lheritier, P. Walsh, S. Haemmerle, M. Wells, I. Nikolaev, M.Maurer
poster icon

Patients treated with ligelizumab achieve freedom from signs and symptoms of chronic spontaneous urticaria regardless of the angioedema status at baseline

K. Sitz, W. Soong, J. A. Bernstein, M. Maurer, A. Giménez-Arnau, E. Hua, C. M. Tafur, T. Severin
poster icon

Complete freedom from chronic spontaneous urticaria signs and symptoms is associated with sleep and dermatology quality-of-life improvements: Data from the phase 2b ligelizumab study

J. A. Bernstein, A. Giménez-Arnau, M. Hide, M. Maurer, K. Sitz, G. Sussman, C-E. Ortmann, M-M. Balp, C. M. Tafur, T. Severin
poster icon

Healthcare resource utilisation among adults with chronic spontaneous urticaria in the United States

M-M. Balp, Y. Geissbühler, A. Mcconnon, J. Gomme, S. J. McKenna, W. Soong
poster icon

Healthcare resource utilisation among adults with chronic inducible urticaria in the United States

Y. Geissbühler, M-M. Balp, A. Mcconnon, J. Gomme, S. J. McKenna, W. Soong
poster icon

Impact of chronic spontaneous urticaria on health-related quality of life in the United States

K. Freedle, D. Patil, M-M. Balp, S. J. McKenna, S. Gupta, B. Balkaran
poster icon

Prevalence and clinical profile of patients with chronic spontaneous urticaria in the USA

D. Patil, K. Freedle, M-M. Balp, S. J. McKenna, S. Gupta, B. Balkaran
poster icon

Remibrutinib (LOU064) for Chronic Spontaneous Urticaria: Time to Complete Urticaria Control

M. Maurer, P. Yamauchi, H. Kanavy , A. Giménez Arnau , J. Reed, P. Staubach, K. Lheritier , P. Walsh, I. Nikolaev, S. Haemmerle, M. Lebwohl

2021

poster icon

Ligelizumab further reduced sleep impairment in patients with chronic spontaneous urticaria previously treated with omalizumab

M. Maurer, K. Sitz, G. Sussman, M. Metz, M. Hide, A.Giménez-Arnau, N. Barbier, E. Hua, R. Janocha, M.M. Balp, T. Severin
poster icon

High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the Phase 2b core study

J.A. Bernstein, M. Maurer, A. Giménez-Arnau, W. Soong, K. Sitz, E. Hua, N. Barbier, A. Barve, T. Severin, R. Janocha

2020

No publication submitted this year

2019

poster icon

Ligelizumab achieves sustained symptom control up to 1 year in the majority of patients with chronic spontaneous urticaria: Results of the  1-year extension study of the Phase 2b trial

J. A. Bernstein, D. Baker, M. Maurer, A. Giménez-Arnau, G. Sussman, A. Barve, E. Hua, T. Severin, R. Janocha

2018

No publication submitted this year

© Copyright 2024 Novartis Pharma AG